Integra LifeSciences Holdings Corporation (IART) Releases Q1 2026 Earnings: Revenue Up but EPS Miss

Integra LifeSciences Holdings Corporation (IART) reported Q1 2026 results with total revenue of $391.9 million, up 2.4% year‑over‑year and ahead of the consensus revenue estimate of $389.5 million.

Gross profit was $217.0 million, up 11.6% year‑over‑year.

Cost of sales totaled $174.9 million, down 7.1% year‑over‑year.

Operating profit came in at $11.5 million, a decline of 174.0% year‑over‑year.

Net income attributable to common shareholders was -$4.6 million, down 81.8% year‑over‑year; diluted earnings per share were -$0.06, a decline of 81.8% versus the prior year and below the estimated $0.41.

Cash flow and balance sheet items:

Cash from operating activities: $9.8 million, down 187.1% year‑over‑year.

Purchases of property, plant and equipment: -$14.8 million, down 48.7% year‑over‑year.

Cash and cash equivalents: $236.8 million, down 1.0% year‑over‑year.

Total liabilities: $2.5 billion, up 0.3% year‑over‑year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Integra LifeSciences Holdings Corporation Insider Trading Activity

Integra LifeSciences Holdings Corporation insiders have traded $IART stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $IART stock by insiders over the last 6 months:

JEFFREY A GRAVES purchased 9,000 shares for an estimated $102,150

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive IART Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

Integra LifeSciences Holdings Corporation Hedge Fund Activity

We have seen 94 institutional investors add shares of Integra LifeSciences Holdings Corporation stock to their portfolio, and 114 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,440,818 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,894,959
DEERFIELD MANAGEMENT COMPANY, L.P. removed 755,656 shares (-95.1%) from their portfolio in Q4 2025, for an estimated $9,385,247
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 615,637 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $7,646,211
QUANTINNO CAPITAL MANAGEMENT LP added 601,738 shares (+250.4%) to their portfolio in Q4 2025, for an estimated $7,473,585
NEUBERGER BERMAN GROUP LLC added 541,996 shares (+35.3%) to their portfolio in Q4 2025, for an estimated $6,731,590
INVENOMIC CAPITAL MANAGEMENT LP added 463,729 shares (+78.3%) to their portfolio in Q4 2025, for an estimated $5,759,514
J. GOLDMAN & CO LP added 292,961 shares (+30.8%) to their portfolio in Q4 2025, for an estimated $3,638,575

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Integra LifeSciences Holdings Corporation Price Targets

Multiple analysts have issued price targets for $IART recently. We have seen 3 analysts offer price targets for $IART in the last 6 months, with a median target of $12.0.

Here are some recent targets:

Ravi Misra from Truist Securities set a target price of $12.0 on 04/15/2026
Joanne Wuensch from Citigroup set a target price of $9.0 on 03/11/2026
Vik Chopra from Wells Fargo set a target price of $12.0 on 02/27/2026